^
    Back
    Association details:
    Biomarker:XIRP2 mutation + TMB-H
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2022
    Title:

    XIRP2 mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC.

    Published date:
    05/26/2022
    Excerpt:
    NSCLC patients with XIRP2 mutation were significantly associated with better PFS (HR = 0.4; 95% CI, 0.21-0.75; P = 0.003) after ICIs therapy, compared with those with wide-type XIRP2. XIRP2 mutation were associated with increased TMB (P< 0.001).
    DOI:
    10.1200/JCO.2022.40.16_suppl.e14573